Main Menu

Dr Alison Tree

Team Leader

The alt text
Dr Alison Tree is a clinical researcher investigating the benefits of profoundly hypofractionated radiotherapy in urological cancers. She is involved in several national and international trials of innovative radiotherapy strategies, and has a particular interest in prostate cancer. Team: Uro-oncology Clinical Trials
+44 20 8661 3271 ORCID 0000-0002-5033-424X


Dr Alison Tree was appointed as a consultant clinical oncologist at The Royal Marsden NHS Foundation Trust in 2014, specialising in urological malignancies. Her MD thesis was on stereotactic body radiotherapy (SBRT) techniques for prostate and oligometastatic cancer.

Her current research interests focus on technical radiotherapy developments in prostate cancer, aiming to make radiotherapy more effective and reduce side effects. Dr Tree leads the Prostate Group in the International MR Linac consortium, which she now also chairs. She is lead GU editor for the International Journal of Radiation Oncology Biology and Physics.

She is currently leading trials in MR-guided prostate radiotherapy (the PRISM trial), boosting dominant intra-prostatic lesions (the DELINEATE trial) and ablating oligoprogressing metastases in advanced prostate cancer (the TRAP trial). Currently her team are recruiting to the HERMES trial which is testing whether prostate cancer can be cured in just 2 fractions and the DESTINATION trials, looking a novel ways to minimise side effects after radiotherapy. She is also involved in the PACE trials, and leads PACE C.

Dr Tree is a member of the Cancer Research UK Convergence Science Centre, which brings together leading researchers in engineering, physical sciences, life sciences and medicine to develop innovative ways to address challenges in cancer.

Convergence Science Centre